Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Spinal Metastases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    75 result(s) found for: Spinal Metastases. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-001376-12 Sponsor Protocol Number: BISMARK 2005 Start Date*: 2005-08-19
    Sponsor Name:University of Sheffield
    Full Title: Cost-effective use of BISphonphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule.
    Medical condition: Advanced breast cancer with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000848-65 Sponsor Protocol Number: 20050244 Start Date*: 2006-09-01
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Cancer (Excluding Breast and Prostate...
    Medical condition: Treatment of bone metastases in subjects with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) HU (Completed) GB (Completed) LT (Completed) DE (Completed) SK (Completed) LV (Completed) SE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000339-93 Sponsor Protocol Number: 20050136 Start Date*: 2006-05-26
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer.
    Medical condition: Treatment of bone metastases in subjects with advanced breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027452 Metastases to bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) NL (Completed) SK (Completed) GB (Completed) AT (Completed) ES (Completed) DE (Completed) LT (Completed) EE (Completed) BE (Completed) SE (Completed) LV (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019216-20 Sponsor Protocol Number: AZ2010 Start Date*: 2010-05-01
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
    Full Title: "Effects of drug treatment with bisphosphonates (zoledronic acid) in the prevention of skeletal events in breast cancer patients with osteoporosis. Significant correlation with some biological para...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001855-12 Sponsor Protocol Number: BO 18040 Start Date*: 2004-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal ...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001854-10 Sponsor Protocol Number: BO18039 Start Date*: 2005-02-16
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in...
    Medical condition: Metastatic Bone Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000608-42 Sponsor Protocol Number: ISRCTN79831382/NovartisCZOL446G2408 Start Date*: 2004-11-19
    Sponsor Name:University of Sheffield
    Full Title: A randomised study to determine whether zoledronic acid adds to the benefits of chemotherapy and/or hormone therapy in the treatment of women with breast cancer. –AZURE STUDY–
    Medical condition: Stage II/III primary breast cancer, with T stage ≥ T1
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006195-11 Sponsor Protocol Number: BC1-06 Start Date*: 2008-03-26
    Sponsor Name:Algeta ASA
    Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    Medical condition: Hormone refractory prostate cancer with skeletal metastases
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027452 Metastases to bone PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003770-23 Sponsor Protocol Number: MO19631 Start Date*: 2006-04-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, two arm, controlled study to compare the efficacy of oral ibandronate treatment versus intravenous zoledronate in patients with symptomatic Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Prematurely Ended) AT (Prematurely Ended) LV (Prematurely Ended) SI (Prematurely Ended) HU (Prematurely Ended) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001101-10 Sponsor Protocol Number: CZOL446G2419 Start Date*: 2004-11-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A prospective, multicenter, randomized phase III study to evaluate the efficacy of Zometa (zoledronic acid) in delaying progression or recurrence in patients with stage III non-small cell lung cancer
    Medical condition: Patients with unresectable stage IIIA and IIIB Non small cell lung cancer (NSCLC) without bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) AT (Completed) IT (Prematurely Ended) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000341-19 Sponsor Protocol Number: 20050103 Start Date*: 2006-05-05
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer
    Medical condition: Metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed) CZ (Completed) HU (Completed) ES (Completed) DE (Completed) NL (Completed) LT (Completed) SK (Completed) EE (Completed) SE (Completed) BE (Completed) LV (Completed) DK (Completed) IT (Completed) GR (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002114-23 Sponsor Protocol Number: BAY88-8223/17096 Start Date*: 2015-10-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe...
    Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002184-34 Sponsor Protocol Number: AK-2016-PC-1 Start Date*: 2016-09-14
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET
    Full Title: Phase II trial: uPAR-PET/CT in Radium-223-dichloride treatment of patients with metastatic castration-resistant prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004614-10 Sponsor Protocol Number: CA209-429 Start Date*: 2017-06-12
    Sponsor Name:University Hospital Tübingen
    Full Title: An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma
    Medical condition: Patients with stage IV melanoma and four or more symptomatic brain metastases, who are not eligible for surgery or radiosurgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003774-16 Sponsor Protocol Number: EIFFEL Start Date*: 2016-06-07
    Sponsor Name:A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie )
    Full Title: Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases
    Medical condition: Renal cell carcinoma patients with bone metastases, with or without visceral metastases.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001284-27 Sponsor Protocol Number: ENHANCE Start Date*: 2022-09-07
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase II trial
    Medical condition: NSCLC
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003207-30 Sponsor Protocol Number: GO29436 Start Date*: 2015-05-11
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXE...
    Medical condition: Stage IV non-squamous non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) BG (Completed) NL (Completed) LT (Completed) PT (Completed) FR (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003968-56 Sponsor Protocol Number: CAAA617C12301 Start Date*: 2021-04-06
    Sponsor Name:Novartis Pharma AG
    Full Title: PSMAddition : An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patien...
    Medical condition: PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004684-20 Sponsor Protocol Number: WO29637 Start Date*: 2015-05-27
    Sponsor Name:Roche Farma S.A en nombre de F. Hoffmann-La Roche LTD
    Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (Anti?PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATEDADVANCED RENAL CELL CARCINOMA
    Medical condition: advanced kidney cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) FR (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 30 16:22:33 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA